Home
HelpTest Code ANCA2 Cytoplasmic Neutrophil Antibodies, Inflammatory Bowel Disease Panel, Serum
Specimen Required
Only orderable as part of a profile. For more information see IBDP2 / Inflammatory Bowel Disease Serology Panel, Serum.
Useful For
Measurement of antineutrophil cytoplastic antibodies as a part of a profile to aid in distinguishing between ulcerative colitis and Crohn disease in patients for whom the specific diagnosis is unclear based on endoscopic, pathologic, and imaging evaluations
This test is not useful for determining the extent of disease in patients with inflammatory bowel disease or determining the response to disease-specific therapy including surgical resection of diseased intestine.
Method Name
Only orderable as part of a profile. For more information see IBDP2 / Inflammatory Bowel Disease Serology Panel, Serum.
Indirect Immunofluorescent Assay (IFA)
Reporting Name
Cytoplasmic Neutrophilic Ab IBD, SSpecimen Type
SerumSpecimen Minimum Volume
0.4 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 21 days | |
| Frozen | 21 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | OK |
| Heat-treated specimen | Reject |
Clinical Information
Inflammatory bowel disease (IBD) refers to 2 diseases-ulcerative colitis (UC) and Crohn disease (CD), both of which result from chronic inflammation in the gastrointestinal (GI) tract.(1) CD is characterized by chronic diarrhea, abdominal pain, and fatigue.(2) In comparison, UC frequently presents with bloody diarrhea that is of an urgent nature.(3) Inflammation in UC most frequently affects the rectum and proximal colon and presents with continue mucosal involvement. In CD, inflammation can affect almost any area of the GI tract and is usually evidenced as patchy, transmural lesions.
Diagnosis of IBD is primarily based on clinical evaluation, endoscopy with biopsy, and imaging studies.(4) Because CD and UC are characterized by GI inflammation, fecal calprotectin can be used to differentiate IBD from noninflammatory conditions such as irritable bowel syndrome (IBS). Fecal calprotectin is useful in excluding IBD as a diagnosis and avoiding unnecessary endoscopic or imaging procedures.
CD and UC are associated with the presence of various antimicrobial and autoantibodies.(5) Patients with UC often have measurable antineutrophil cytoplasmic antibodies (ANCA), which react with as yet uncharacterized target antigens in human neutrophils; in contrast, patients with CD often have measurable IgA and/or IgG antibodies, which react with cell wall mannan of Saccharomyces cerevisiae. Despite these associations, current guidelines indicate that testing for these antibodies is not sufficiently sensitive for use in the diagnosis of IBD.(2,3) Rather, these antibodies should be limited to distinguishing between CD and UC in cases where the specific diagnosis is unclear based on pathologic and imaging studies.
Reference Values
Only orderable as part of a profile. For more information see IBDP2 / Inflammatory Bowel Disease Serology Panel, Serum.
Interpretation
The presence of antineutrophil cytoplasmic antibodies (ANCA) in the absence of IgA and IgG anti-Saccharomyces cerevisiae antibodies (ASCA) is consistent with the diagnosis of ulcerative colitis; the presence of IgA and IgG ASCA in the absence of ANCA is consistent with Crohn disease.
Cautions
Results from this test should not be exclusively relied upon to establish the diagnosis of ulcerative colitis (UC) or Crohn disease (CD) or to distinguish between these 2 diseases. Antineutrophil cytoplasmic antibodies (ANCA) are most useful for distinguishing between UC and CD when assessed in conjunction with Saccharomyces cerevisiae IgA and IgG antibodies (ASCA).
Some patients with CD have detectable ANCA, and some patients with UC have detectable IgA and/or IgG (ASCA). Some patients with UC or CD do not have detectable ANCA, IgA ASCA, or IgG ASCA.
ANCA results may be reported as indeterminate if interfering antinuclear antibodies are present.
Method Description
Antineutrophil cytoplasmic antibodies (ANCA) are detected qualitatively using an in-house developed method with a substrate of ethanol-fixed, human neutrophils and fluorescein conjugated, antihuman IgG antibody as a detection protein. Results of the test for ANCA are reported as positive, negative, or indeterminate.(Unpublished Mayo method)
Day(s) Performed
Monday through FridayPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86036
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| ANCA2 | Cytoplasmic Neutrophilic Ab IBD, S | 17355-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 610030 | Cytoplasmic Neutrophilic Ab IBD, S | 17355-9 |
| 614542 | ANCA2 Interpretation | 49308-0 |